Earli

Executive Summary

Earli is a South San Francisco-based biotechnology company pioneering a novel approach to cancer therapy by programming cancer cells to reveal and eliminate themselves. Founded in 2018, Earli leverages artificial intelligence to design highly specific genetic switches that activate exclusively in cancer cells, turning them into in vivo factories that produce their own immune therapies. This platform aims to overcome the fundamental challenge of selectively targeting malignant cells while sparing healthy tissue, potentially transforming cancer into a benign experience. The company's technology combines synthetic biology, AI-driven design, and immunotherapy to create a self-amplifying therapeutic response within tumors. Earli's approach is differentiated from traditional cancer treatments by its focus on in situ reprogramming rather than systemic delivery of therapeutics. By exploiting tumor-specific transcriptional signatures, the genetic switches can drive expression of a variety of payloads, including cytokines, checkpoint inhibitors, or other immunomodulators. This strategy minimizes off-tumor toxicity and could enable durable, localized immune responses. While still in preclinical development, Earli's platform has the potential to address a wide range of solid tumors. The company's future success hinges on demonstrating proof-of-concept in animal models and advancing toward clinical trials, as well as securing partnerships or funding for further development.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data in Animal Models60% success
• Q4 2026Series A or B Financing Round70% success
• H1 2027IND-Enabling Studies Initiation40% success